1. Home
  2. STAA vs ODTX Comparison

STAA vs ODTX Comparison

Compare STAA & ODTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo STAAR Surgical Company

STAA

STAAR Surgical Company

HOLD

Current Price

$22.66

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Logo Odyssey Therapeutics Inc. Common Stock

ODTX

Odyssey Therapeutics Inc. Common Stock

N/A

Current Price

$24.63

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
STAA
ODTX
Founded
1982
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Ophthalmic Goods
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.3B
IPO Year
1995
2025

Fundamental Metrics

Financial Performance
Metric
STAA
ODTX
Price
$22.66
$24.63
Analyst Decision
Buy
Analyst Count
9
0
Target Price
$22.81
N/A
AVG Volume (30 Days)
874.6K
149.1K
Earning Date
05-12-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.26
N/A
Revenue
$239,442,000.00
N/A
Revenue This Year
$30.82
N/A
Revenue Next Year
$8.41
N/A
P/E Ratio
$90.85
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.59
$15.10
52 Week High
$35.87
$29.05

Technical Indicators

Market Signals
Indicator
STAA
ODTX
Relative Strength Index (RSI) 47.81 49.69
Support Level $23.27 $22.89
Resistance Level $24.26 $28.53
Average True Range (ATR) 0.82 2.15
MACD 0.17 -0.27
Stochastic Oscillator 70.13 14.03

Price Performance

Historical Comparison
STAA
ODTX

About STAA STAAR Surgical Company

Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company offers two types of products: Implantable Collamer lenses (ICL), which are used in refractive surgery. The company generates almost all of its revenue from the sale of its ICL products. Geographically, the company generates key revenue from Foreign sales.

About ODTX Odyssey Therapeutics Inc. Common Stock

Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.

Share on Social Networks: